To validate the immunogenicity of our predicted tumor antigens, we used dendritic cells (DCs) electroporated with TOFU mRNA as highly effective APCs, capable of eliciting both CD4 + and CD8 + T-cell responses [52, 53]. The gene discussed is CD8A; the disease is neoplasm.